GSK Resolves Legal Dispute with Kimbrow, Denies Ranitidine Cancer Risk
GSK and Ronald Kimbrow settle lawsuit privately; GSK denies culpability; case dismissed.
In order to resolve the lawsuit he brought in Illinois state
court, Ronald Kimbrow and GSK have
negotiated a private settlement. In this settlement, GSK disavows all
culpability. As for GSK, the case will now be dismissed.
The scientific community has come to the conclusion that
there is insufficient evidence to support any concern that ranitidine raises
the risk of cancer, based on 16 epidemiological studies that examined data
related to ranitidine usage in humans.
GSK is committed to maintaining a strong self-defence and
handling this legal dispute in a way that benefits the firm and its investors.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Más de Pharma News
Todos los artículos →
Ab Science revisa los cronogramas de los ensayos tras tres inspecciones GCP
Novo Nordisk firma un acuerdo de $2.6B con Hengrui por un GLP-1 oral
Discussion